TSIEX01:	Duration of Treatment; Safety Analysis Set (Study jjcs - core)							
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	Difference in Means (95% CI) 	Difference in Means (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
Parameter 	N=53 	N=73 	N=126 	N=59 	  	  	
Durationa, ([unit]) 	 	 	 	 	 	 	
Mean (SD) 	17.41 (11.408) 	20.46 (10.198) 	19.18 (10.786) 	18.64 (10.656) 	-1.23 (-5.23, 2.77) 	1.82 (-1.88, 5.52) 	
Median 	16.10 	21.20 	18.90 	18.60 	 	 	
Min, max 	0.2, 35.4 	0.1, 37.9 	0.1, 37.9 	0.9, 37.2 	 	 	
Interquartile range 	8.30, 27.80 	14.70, 28.10 	11.30, 28.00 	9.30, 26.30 	 	 	
Total treatment (subject years) 	922.9 (76.9) 	1493.8 (124.5) 	2416.7 (201.4) 	1099.9 (91.7) 	 	 	
 	 	 	 	 	 	 	
Duration of treatment, n (%) 	 	 	 	 	 	 	
0 to <3 months 	7 (13.2%) 	4 (5.5%) 	11 (8.7%) 	2 (3.4%) 	 	 	
3 to <6 months 	5 (9.4%) 	5 (6.8%) 	10 (7.9%) 	5 (8.5%) 	 	 	
6 to <9 months 	3 (5.7%) 	3 (4.1%) 	6 (4.8%) 	7 (11.9%) 	 	 	
9 to <12 months 	4 (7.5%) 	2 (2.7%) 	6 (4.8%) 	7 (11.9%) 	 	 	
12 to <15 months 	6 (11.3%) 	8 (11.0%) 	14 (11.1%) 	5 (8.5%) 	 	 	
15 to <18 months 	3 (5.7%) 	10 (13.7%) 	13 (10.3%) 	3 (5.1%) 	 	 	
18 to <21 months 	5 (9.4%) 	4 (5.5%) 	9 (7.1%) 	5 (8.5%) 	 	 	
21 to <24 months 	1 (1.9%) 	7 (9.6%) 	8 (6.3%) 	5 (8.5%) 	 	 	
24 to <27 months 	3 (5.7%) 	6 (8.2%) 	9 (7.1%) 	6 (10.2%) 	 	 	
27 to <30 months 	6 (11.3%) 	9 (12.3%) 	15 (11.9%) 	2 (3.4%) 	 	 	
30 to <33 months 	5 (9.4%) 	4 (5.5%) 	9 (7.1%) 	3 (5.1%) 	 	 	
33 to <36 months 	5 (9.4%) 	9 (12.3%) 	14 (11.1%) 	5 (8.5%) 	 	 	
36 to <39 months 	0 	2 (2.7%) 	2 (1.6%) 	4 (6.8%) 	 	 	
 	 	 	 	 	 	 	
Durationb, n (%) 	 	 	 	 	 	 	
<1 month 	4 (7.5%) 	1 (1.4%) 	5 (4.0%) 	1 (1.7%) 	 	 	
≥1 month 	49 (92.5%) 	72 (98.6%) 	121 (96.0%) 	58 (98.3%) 	 	 	
≥2 months 	46 (86.8%) 	71 (97.3%) 	117 (92.9%) 	58 (98.3%) 	 	 	
≥3 months 	46 (86.8%) 	69 (94.5%) 	115 (91.3%) 	57 (96.6%) 	 	 	
≥6 months 	41 (77.4%) 	64 (87.7%) 	105 (83.3%) 	52 (88.1%) 	 	 	
≥12 months 	34 (64.2%) 	59 (80.8%) 	93 (73.8%) 	38 (64.4%) 	 	 	
≥24 months 	19 (35.8%) 	30 (41.1%) 	49 (38.9%) 	20 (33.9%) 	 	 	

a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1]. 	
a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1].	
a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1].	
a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1].	
a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1].	
a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1].	
a Duration of treatment is defined as [(date of last dose of study treatment – date of first dose of study treatment) +1].	
b Subjects are summarized in all applicable duration categories. 	b Subjects are summarized in all applicable duration categories.	b Subjects are summarized in all applicable duration categories.	b Subjects are summarized in all applicable duration categories.	b Subjects are summarized in all applicable duration categories.	b Subjects are summarized in all applicable duration categories.	b Subjects are summarized in all applicable duration categories.